Beyond Repair. Toward Regeneration.

Introducing the Cellionyx V9 (V-Series) & Cytomotion™ platform. A first-in-class, non-invasive electroceutical and bioelectric medicine system that simultaneously restores arterial perfusion, evacuates deep interstitial edema, switches pro-inflammatory macrophages to regenerative phenotypes, and re-energizes hypoxic peripheral nerves across 23 high-need clinical indications.

Explore The V9 Technology Hospital Doppler & NIRS Science

When the Body's Blueprint for Healing Stalls.

Across peripheral neuropathy, diabetic foot ulcers, post-surgical and post-C-section tissue trauma, fibromyalgia, and lymphedema, tissues become trapped in a self-reinforcing cycle: microvascular ischemia, interstitial fluid stagnation, chronic pro-inflammatory (M1) macrophage lock, and cellular ATP starvation. Conventional drugs and passive therapies merely mask symptoms while the underlying microvascular and bioelectric deficit continues.

The 4-Fold Root Cause:

  • Microvascular ischemia & capillary hypoxia (starved vasa nervorum & wound beds)
  • Interstitial edema & lymphatic stasis (hydrostatic capillary compression)
  • Persistent M1 pro-inflammatory lock & fibrotic scar tethering
  • Depleted transepithelial potential & stalled axonal mitochondrial transport

Measured on Hospital-Grade Diagnostic Instruments.

Evaluated using longitudinal hospital GE LOGIQ e Color & Spectral Triplex Doppler Ultrasound and 6-channel spatially resolved Artinis PortaMon MKIII Near-Infrared Spectroscopy (NIRS), the Cellionyx V9 (V-Series) conformal garment platform produces four simultaneous, objective physiological shifts that persist after the device is turned off:

+94.9%
Sustained Leg Arterial Volume Flow (+5 Min Post-OFF on GE LOGIQ e Doppler; +46.1% in Wrist Radial Artery)
+114.2%
Deep Venous Return Surge During Therapy (+51.1% Sustained Post-OFF Without Mechanical Compression)
-10.1 µM
Deep Interstitial Fluid Evacuation (Artinis PortaMon MKIII 6-Channel NIRS Total Hemoglobin Shift)
+3.4 pp
Deep-Capillary Tissue Saturation Index (TSI%) Surge Extending Into Post-Therapy Washout

A Universal Microvascular & Cellular Rescue Platform.

Microvascular & Neural Rescue

Microvascular & Neural Rescue

Re-perfuse ischemic peripheral nerves (vasa nervorum) and distal microvascular beds via shear-stress endothelial nitric oxide (eNOS) activation—supporting peripheral neuropathy, chemotherapy-induced neuropathy (CIPN), and limb salvage.

Deep Edema Evacuation & Pain Gating

Edema Evacuation & Pain Gating

Mobilize trapped interstitial fluid across superficial and deep tissue layers while engaging endogenous Conditioned Pain Modulation (CPM) and clearing acidic algesic metabolites in fibromyalgia, post-C-section recovery, and lymphedema.

Directed Galvanotaxis & M2 Repair

Directed Galvanotaxis & M2 Repair

Harness proprietary EDCMC bioelectric fields to direct keratinocyte, fibroblast, and endothelial migration while polarizing macrophages from pro-inflammatory M1 to pro-healing M2 phenotypes across wounds and surgical incisions.

Explore All 23 Clinical Indications

From a Founder's Vision to Clinically-Proven Results.

Cellionyx was founded by Sanjay Bagai on a singular mission: to engineer healing at the cellular level. After seeing the limitations of conventional therapies firsthand, he assembled a world-class team of engineers, scientists, and clinical advisors to build a technology that works with the body's intelligence, not just on it.

Read Our Story

Ready to Transform Patient Outcomes?

Request a demo to see how Cytomotion™ can integrate into your practice and revolutionize your approach to healing.